

# **Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage (CLUTCH)**

## **Principal Investigator:**

Adnan I. Qureshi, MD, Professor of Neurology and Program Director  
Endovascular Surgical Neuroradiology program, University of Missouri, Columbia, MO.

## **Steering Committee:**

Fawaz Al-Mufti, MD Vice Chair of Neurology (Research), Associate Professor of Neurology, Neurosurgery and Radiology, New York Medical College, Director of the Neuroendovascular Surgery Fellowship, Director of Neurocritical Care Unit, Westchester Medical Center at New York Medical College, NY.

Joao A. Gomes, MD, FAHA FCCM Head, Neurointensive care Associate Professor of Neurology, Lerner College of Medicine Cleveland Clinic, Cleveland, OH.

Alejandro A. Rabinstein, M.D. Professor of Neurology, Chair, Neurocritical Care and Hospital Neurology, Mayo Clinic, Rochester, MN.

Ali Seifi, M.D., FACP, FNCS, FCCM, Professor of Neurosurgery and Neuro Critical Care Department of Neurosurgery Director, Neuro Intensive Care Unit Fellowship Director, Neuro Critical Care Distinguished Star Educator University of Texas Health at San Antonio, TX.

Prof. Dr. Thorsten Steiner, MME, FESO, FEAN Chefarzt: Klinik für Neurologie, Varisano Klinikum Frankfurt Höchst Affiliated Professor, Faculty of Health and Medical Sciences, Universität Copenhagen Chair: Intracerebel Hemorrhage (ICH) Committee European Stroke Organization (ESO) Wissenschaftlicher Mitarbeiter der Neurologische Klinik, Universität Heidelberg, Germany.

## **Data Coordinating Unit:**

Chi-Ren Shyu, Ph.D., FACMI, FAMIA Director, Institute for Data Science and Informatics Paul K. and Dianne Shumaker Professor, College of Engineering, University of Missouri, Columbia, MO.

## **Chiesi USA:**

Hijrah El Sabae, PharmD Medical Affairs Sr. Scientist Chiesi USA.

## **Project Coordinator:**

Pashmeen Lakhani, MB;BS Zeenat Qureshi Stroke Institute, Columbia, MO.


Study Registration: <https://clinicaltrials.gov/study/NCT06402968>

## HYPOTHESIS

**Primary hypothesis:** We hypothesize that among hypertensive patients with intracerebral hemorrhage (ICH), the likelihood of reaching a clinically determined systolic blood pressure (SBP) target with stability within 60 minutes of initiation of treatment will be  $\geq 7.5\%$  greater for patients treated with intravenous (IV) clevidipine compared with those treated with an alternate IV antihypertensive regimen given per institutional standard.

**Primary endpoint:** SBP target with stability is defined as achieving a SBP of less than 150 mm Hg, but greater than 130 mm Hg, plus two subsequent consecutive recordings, taken at least 15 minutes apart, remaining within that 130-150 mm Hg range. Achieving therapeutic target within 60 minutes of initiating treatment is recommended by American Heart Association/ American Stroke Association (AHA/ASA) guidelines<sup>1</sup> to reduce the risk of hematoma enlargement (Class of recommendation 2A, benefit exceeds risk, level of evidence B-R, moderate quality evidence from one of more randomized clinical trial or meta-analysis of randomized controlled trials). The time to reach SBP target with stability will be defined by time interval between the SBP at time of initiating IV clevidipine or alternate IV antihypertensive regimen and first of the three consecutive recordings with SBP of less than 150 mm Hg and greater than 130 mm Hg (see Figure 1). The primary endpoint will be determined centrally using the SBP data exported into the enrolling institution's electronic data collection (EDC) system, with filtering to ensure sampling of SBP data at 15 minutes intervals. The programming within the EDC system will calculate the time to reach SBP target with stability, and will therefore avoid ascertainment bias.

Figure 1. Definition of the time to reach SBP target with stability



## OBJECTIVES

**Primary Objective:** To compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen. SBP target with stability is defined as achieving a SBP of less than 150 mm Hg and greater than 130 mm Hg with two subsequent consecutive recordings at least 15 minutes apart that show SBP of less than 150 mm Hg and greater than 130 mm Hg.

### Secondary Objectives

1. To compare the median time to reach target SBP (130 mm -150 mm Hg) after initiation of treatment among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH.
2. To compare the proportion of subjects with ICH who reach SBP target among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen within 30 minutes of enrollment.<sup>2</sup>
3. To compare the time-in-target range (TTR), which is the proportion of time with SBP within a defined range after initiation of treatment among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH.<sup>3</sup>
4. To compare the rate of hematoma enlargement at 24 hours among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH. Hematoma enlargement is defined by a 33% greater increase in hematoma volume at 24 hours compared with baseline hematoma volume.
5. To compare the Standard Deviation (SD) of the mean value of SBP within first 8 hours after initiation of treatment among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen among subjects with ICH. The SD is a measure of SBP variability previously used in previous studies.<sup>4,5</sup>
6. To compare the rate of new ischemic lesions among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH. New ischemic lesions will be defined by the presence of hyperintensities on diffusion weighted imaging (DWI) if hyperintense signal is relative to surrounding tissue and distinct from ICH with correlation on apparent diffusion coefficient map. New ischemic lesions will be identified by brain magnetic resonance imaging (MRI) acquired between 24 hours and 7 days.
7. To compare the rate of functional independence among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH. Functional independence will be defined by the modified Rankin scale (mRS) score of 0-2:  
0 = No symptoms at all; 1 = No significant disability despite symptoms; able to carry out all usual duties and activities, and 2 = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance. The outcome will be ascertained by a designated investigator certified in mRS scale assessment and not involved in-hospital management of subjects.
8. To compare the rate of neurological deterioration within 24 hours among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH. Neurologic deterioration will be defined as a decrease from baseline of 2 or more points in Glasgow Coma Scale score or an increase of 4 or more points in the National Institutes of Health Stroke Scale score that was not associated with sedation or hypnotic agent use and was sustained for at least 8 hours<sup>6</sup>.
9. To compare the rate of acute kidney injury (AKI) within 72 hours among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen among subjects with ICH. AKI will be identified based on chemistry panel was performed at baseline and daily serum creatinine measurements up to Day 7 or discharge (whichever comes first). AKI will be defined based on the guidelines provided by the Kidney Disease: Improving Global Outcomes (KDIGO) definition: Increase in serum creatinine by 0.3 mg/dL or more within 48 hours OR. Increase in serum creatinine to 1.5 times baseline or more within the last 7 days OR. Urine output less than 0.5 mL/kg/h for 6 hours<sup>7</sup>
10. To compare the rate of serious adverse events (SAE) related to IV antihypertensive medication within 24 hours of initiating treatment among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen among subjects with ICH. SAEs include events that result in death, are life threatening (an event in which the patient was at risk of death at the

time of the event), require or prolong inpatient hospitalization, or result in persistent or significant disability or incapacity.<sup>8</sup> Relatedness is a term intended to indicate that a determination has been made by the treating clinician that the event had a reasonable possibility of being related to exposure to the intervention. This assessment of causality may be based on factors such as biological plausibility, prior experience with the product, and temporal relationship between product exposure and onset of the event, and de-challenge (discontinuation of the product to determine if the SAE resolves) and rechallenge (reintroduction of the product to determine if the SAE recurs).

11. To compare the number of hypotensive episodes (defined as SBP <90 mm Hg) and symptomatic hypotension episodes (defined as SBP <90 mm Hg requiring IV vasopressors or evidence of organ hypoperfusion which includes change in level of consciousness, new or worsening of focal neurological deficits, myocardial ischemia, and oliguria) within 24 hours of initiating treatment among patients treated with IV clevidipine and those treated with alternate IV antihypertensive regimen.<sup>6</sup>

## **BACKGROUND**

### **Acute hypertensive response**

Acute hypertensive response, which is the elevation of blood pressure (BP) above normal and pre-morbid values that occurs within the first 24 hours of stroke onset,<sup>9</sup> can be seen in 75% of patients with acute ICH.<sup>10</sup> Treatment of acute hypertensive response remains a priority in patients with ICH due to its association with hematoma expansion (HE), perihematomal edema, and death.<sup>11-16</sup> Recent studies suggest that reduction of BP may be well tolerated because of reduced metabolism (hibernation) and preserved autoregulation in the perihematomal region.<sup>17-19</sup>

### **Data from randomized clinical trials**

The Intensive BP Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) randomly assigned 2794 ICH patients within 6 hours of symptom onset to immediate intensive (target SBP <140 mm Hg within 1 h of treatment) or guideline-directed (target <180 mm Hg) SBP management.<sup>20</sup> Among the 2794 participants for whom the primary outcome could be determined, 719 of 1382 participants (52.0%) receiving intensive treatment, as compared with 785 of 1412 (55.6%) receiving guideline-recommended treatment, had a primary outcome event. The primary outcome (poor outcome, defined as death or major disability [per mRS score] at 90 days after randomization) occurred in 52.0% and 55.6% of patients randomized to intensive and standard treatments, respectively (odds ratio [OR] with intensive SBP reduction, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P=0.06). The ordinal analysis showed significantly lower mRS scores with intensive treatment (OR for greater disability, 0.87; 95% CI, 0.77 to 1.00; P=0.04). The Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-2) trial randomized 1000 patients within 4-5 h of the onset of symptoms to immediate, intensive (target SBP 110-139 mm Hg) or guideline-directed (140-179 mm Hg) BP management with IV nicardipine, with the aim of achieving these target ranges within 2 hours after randomization.<sup>6</sup> The primary outcome of death or disability (mRS score of 4 to 6) at 90 days post randomization was observed in 38.7% and 37.7% of the patients randomized to intensive and standard treatments, respectively (adjusted relative risk of 1.04, 95%CI, 0.85 to 1.27). There were several key differences between INTERACT-2 and the ATACH-2 trial that are important for interpretation. In INTERACT-2, only 48% of the 2839 participants underwent randomization with an initial SBP of 180 mm Hg or more, whereas all the participants in the ATACH-2 trial had an initial SBP of 180 mm Hg or more. Primary treatment failure was seen in 66% of the participants within 1 hour after randomization in INTERACT2 and in 12.2% of those in the intensive-treatment group within 2 hours after randomization in the ATACH-2 trial.<sup>6,20</sup>

A pre-planned pooled analysis of INTERACT-2 and the ATACH-2 trial analyzed 3829 patients who were randomized at a median time from the onset of ICH of 3.6 h (2.7-4.4). Overall, the mean magnitude of early SBP reduction was 29 mm Hg (standard deviation of 22 mm Hg), and the subsequent mean SBP achieved was 147 mm Hg.<sup>21</sup> The SBP achieved (the mean of the SBP measurements at five time points between 1 h and 24 h) was associated with functional status (improvement per 10 mm Hg increase adjusted OR 0.90 [95% CI 0.87-0.94],  $p < 0.0001$ ), good outcome [mRS 0-3] (OR 0.90, 95% CI 0.85-0.95,  $p < 0.0001$ ), and functional independence [mRS 0-2] (OR 0.91, 95% CI 0.87-0.96,  $p = 0.0009$ ). The SBP achieved was also associated with HE (>6 ml increase from baseline) (OR 1.16, 95% CI 1.06-1.27,  $p = 0.0008$ ). The magnitude of SBP reduction (the difference between SBP at randomization and the lowest attained SBP within 1 h) was associated with good outcomes and functional independence. Absolute reduction of SBP of both 20–40 mm Hg and 40–60 mm Hg within 1 hour were associated with good outcome and functional independence (vs reduction of <20 mm Hg). A meta-analysis of five studies, including 4360 patients with acute ICH<sup>22</sup> reported that the risk of death or dependency at 90 days was non-significantly lower with intensive SBP reduction compared with standard SBP reduction (OR: 0.91; 95% CI: 0.80 to 1.02),  $p = 0.106$ ). Intensive SBP reduction was associated with a trend towards lower risk of HE compared with standard SBP reduction (OR: 0.82; 95% CI: 0.68 to 1.00,  $p = 0.056$ ). Another meta-analysis of 50 trials involving 11 494 patients, including patient-level data from 6221 patients (median time from symptom onset to randomization of 3.8 hours) reported that active/intensive BP-lowering interventions within 7 days had no effect on ordinal analysis of mRS scores compared with placebo/guideline treatment (OR 0.97, 95% CI 0.88 to 1.06;  $p = 0.50$ ). Active/intensive BP-lowering interventions reduced absolute (>6 ml, OR 0.75, 95% CI 0.60 to 0.92;  $p = 0.0077$ ) and relative ( $\geq 33\%$ , adjusted OR 0.82, 95% CI 0.68 to 0.99;  $p = 0.034$ ) HE.

### **Blood pressure fluctuation**

Recent studies have highlighted the importance of BP variability in acute phase of ICH. An analysis of FAST-MAG trial (Field Administration of Stroke Therapy-Magnesium)<sup>23</sup> demonstrated that SD, coefficient of variation, and successive variation of BP recorded by paramedics in the field and during the first 24 hours of hospital course in patients with ICH were associated with death or disability at 3 months. Neither mean nor maximum systolic BP was associated with these outcomes in multivariable analysis. Another analysis of the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI)-ICH study cohort<sup>24</sup> found that SD of SBP in first 24 hours was associated with neurological deterioration, and successive variation in the SD of SBP in first 24 hours was associated with death or disability at 3 months. Another analysis of the ATACH-2 trial<sup>25</sup> showed that SBP variability in the first 24 hours was associated with death or disability at 90 days. An analysis of the INTERACT-2<sup>26</sup> found that the SD of SBP in the first 24 hours had a significant linear association with death or major disability at 90 days. In a pooled analysis of INTERACT 2 and ATACH 2,<sup>27</sup> higher SBP variability (the SD of the same measures between 1 hour and 24 hours) was significantly associated with death within 90 days, while lower SBP variability was associated with improved outcomes.


### **Current guidelines**

The AHA/ASA guidelines<sup>1</sup> consider lowering SBP to a target range of 130 to 140 mm Hg (from initial SBP between 150-220 mm Hg) to be safe, and may be reasonable in improving functional outcomes in patients presenting with acute ICH of mild to moderate severity. Initiating treatment as soon as possible and careful titration of antihypertensive agents to ensure continuous, smooth, and sustained control of BP were recommended. Acute lowering of SBP to <130 mm Hg in ICH patients is potentially harmful and should be avoided. The safety and efficacy of intensive SBP reduction in patients with SBP >220 mm Hg and in those with large and more severe ICHs (at risk for cerebral perfusion compromise attributable to high intracranial pressure), require more study because these patients were not adequately represented in

previous trials. The AHA/ASA guidelines<sup>1</sup> identify the need for more research to better delineate the importance of various BP measures, including the selection and administration method (bolus versus drip) of antihypertension agent, absolute versus relative reduction in SBP, and prognostic significance of the magnitude of SBP reduction during the first few hours<sup>1</sup>. **The current guidelines emphasize both careful SBP reduction (that is, with avoidance of “overshoot” correction) and avoidance of fluctuation of SBP during treatment.**

## DESIGN

CLUTCH is designed as a non-randomized cluster study with adequate number of clusters and subjects to allow statistical comparison between BP reduction strategies on primary outcome. Overall, 50 hospitals (30 hospitals in United States [USA] and 20 hospitals in Europe and possibly Mexico) will be included. Of those 50 hospitals, 25 hospitals will be “designated clevidipine hospitals” and 25 hospitals will be “designated non-clevidipine hospitals”. To participate, sites will be required to fulfil certain eligibility criteria: (i) have an established acute stroke care program for the management of patients with ICH (i.e. in an acute stroke unit or intensive care unit [ICU]), (ii) admit an adequate number of ICH patients (approximately 50 or more) per annum for the recruitment to be feasible within a reasonable time period. The site must adhere to the protocol, collecting data on patients’ stay in hospital and the 90- and 180-day clinical outcomes. A clinical study agreement will be signed and IRB approval will be secured before the commencement of recruitment. There is a nested stepped wedge design that will allow data collection at sites in Europe and Mexico where patients will likely be exposed to IV clevidipine over time as the study progresses.<sup>28</sup> We anticipate that approximately 8 hospitals will be included in the nested stepped wedge design and these hospitals will be counted in the first part as “designated non-clevidipine hospitals” and in the second part as “designated clevidipine hospitals” (see Figure 2). An observational cohort of patients with ICH with initial SBP  $\geq 220$  mm Hg will be included to help inform the association between SBP reduction and outcomes in that cohort. We expect that approximately 200 patients will be included in this observational cohort, based on a post hoc analysis of ATACH-2 that found that 22.8% of the ICH patients recruited in the study had an initial SBP  $\geq 220$  mm Hg.<sup>29</sup>



The non-randomized cluster design was chosen over individual patient randomization based on extensive review of advantages and disadvantages of both designs and independent assignment of value assigned to each attribute by the Steering Committee (see Table 1). The non-randomized cluster design was chosen to provide data on patients with ICH treated in general practice rather than in a highly selected patient cohort that would be studied in a randomized clinical trial. For example, in ATACH-2, a total of 8532 patients with ICH were screened, of whom 1000 (12%) underwent randomization. Inclusion of patients with moderate to severe grade ICH was challenging in the ATACH 2 trial.<sup>6</sup> The non-randomized cluster design is expected to include  $\approx 70\%$  of patients with ICH seen at the participating hospitals. **The results are expected to be reflective of and generalizable to current practice of SBP reduction in patients with ICH in general practice.** We expect that the SBP reduction will be initiated earlier in non-randomized cluster design because extensive screening, eligibility conformation, and informed consent is not required (unlike randomized controlled trials) prior to being enrolled in the trial. Early initiation of SBP reduction prior to randomization in the trial was associated with lower rates of HE and functional independence at 90 days in the ATACH-2.<sup>30</sup>

**Table 1. Comparison of individual patient randomization versus cluster trial (by site) methodology**

Characteristics	Individual patient randomization	Cluster trial (by site)
Scientific hierarchy	Level 1	Level 2
Real world population recruited	Moderate likelihood	High likelihood
Selection bias	Patients with lower disease severity	Patients with higher disease severity
Informed consent	Necessary prior to randomization unless waiver of consent	Not required prior to care; deferred consent for data collection
Recruitment uptake	Low to moderate	High
Best suited	Single intervention	Group of interventions
Treatment allocation	Permuted-block randomization, adaptive biased-coin randomization, stratified randomization, minimization algorithms	Each group is randomly assigned to a study intervention by center, with sites matched by propensity scoring
Confounding	Patient characteristics with prognostic significance	Site characteristics influencing patient outcome
Randomization	Time sensitive immediately after enrollment	Sites pre-selected and no requirement for time sensitive randomization
Change over time	Adaptive randomization	Stepped-wedge design
Masking of treatment allocation	Blinded assessments, masking of research and non-research staff necessary	Blinded assessments and masking of research and non-research staff not necessary
Change in care over time/standardization of non-trial related care	Standardize and monitor by patient audits	Attempt to standardize and difficult by site audits

Cross overs	Possible	Unlikely
Sample size	80% power at alpha of 0.05-smaller	Larger sample size to adjust for measures of the degree of similarity among members of a cluster (intra-class correlation coefficient, ICC)
Statistical analysis	Post hoc adjustment (pre-specified)	Post hoc adjustment (pre-specified), more difficult to pre-specify
Length of recruitment and trial duration	Longer with site initiation, IRB approval, and trial procedures	Shorter with standardization of data ascertainment and reporting
Cost	Higher in screening, recruiting, and randomizing large numbers of individuals	Lower and overlaps with standard of care

Prior to participation, each site will complete a questionnaire that inquiries about the total annual spontaneous ICH admissions (validated through review of institutional data), and documentation of last 25 patients with spontaneous ICH (ICH score<sup>31</sup> and in-hospital mortality) to ensure balance between “designated clevidipine hospitals” and “designated non-clevidipine hospitals”. The ICH score<sup>31</sup> is the sum of individual points assigned as follows: Glasgow Coma Scale (GCS) score 3 to 4 (=2 points), 5 to 12 (=1), 13 to 15 (=0); age  $\geq 80$  years yes (=1), no (=0); infratentorial origin yes (=1), no (=0); ICH volume  $\geq 30$  cm<sup>3</sup> (=1),  $< 30$  cm<sup>3</sup> (=0); and intraventricular hemorrhage (IVH) yes (=1), no (=0).

## INTERVENTION

The treatment goals are consistent with the AHA/ASA guidelines<sup>1</sup> for US sites and consistent with the European Stroke Organisation (ESO)-Karolinska Stroke Update Conference<sup>32</sup> guidance for European sites. The AHA/ASA guidelines<sup>1</sup> state that in ICH of mild to moderate severity presenting with SBP between 150 and 220 mmHg, acute lowering of SBP to a target of 140 mmHg with the goal of maintaining in the range of 130 to 150 mmHg is safe and may be reasonable (class of recommendation 2b, benefit greater than risk, level of evidence B-R, moderate quality evidence from one of more randomized clinical trial or meta-analysis of randomized controlled trials). The guidelines further state medication titration to ensure continuous smooth and sustained control of SBP, avoiding peaks and large variability in SBP, can be beneficial. (Class of recommendation 2A, benefit exceeds risk, level of evidence B-NR, moderate quality evidence from one of more non-randomized studies, observational studies, registry data). The ESO-Karolinska Stroke Update Conference<sup>32</sup> recommends lowering SBP to below 140 mm Hg but to keep it above 110 mm Hg and to avoid SBP reduction of  $> 90$  mm Hg to prevent AKI (grade B, support from one randomized controlled trial or one statistical review). The ESO guidelines on BP management acknowledge that in patients with acute ( $< 24$  hours from symptom onset) ICH, there is continued uncertainty over the benefits and risks (advantages/disadvantages) of intensive SBP lowering on functional outcome.<sup>33</sup> In patients with hyperacute ( $< 6$  hours) ICH, the ESO suggests lowering SBP to below 140 mmHg (and to keep it above 110 mmHg) to reduce HE (quality of evidence: moderate strength of recommendation: weak).

## IV CLEVIDIPINE PROTOCOL:

Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated



with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.

#### **ALTERNATE IV ANTIHYPERTENSIVE REGIMEN:**

The alternate IV antihypertensive regimen would be the institutional standard management at designated “non-clevidipine hospitals”. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.

### **SELECTION OF SUBJECTS**

#### **Inclusion Criteria**

1. Age 18 years or older and less than 90 years.
2. Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset.
3. Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect.
4. Initial National Institutes of Health Stroke Scale (NIHSS) score of 4 or greater.
5. Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment.
6. Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement <60 cc.
7. Admission SBP greater than 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for exclusion of ICH patients with initial SBP  $\geq$ 220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP  $\geq$ 220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days.<sup>29</sup>
8. Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow up visits.
9. Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA/ASA guidelines.
10. Patients who will undergo surgical evacuation consistent with AHA/ASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery/intervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)/ Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with  $\leq$  5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention.<sup>34,35</sup>
11. Patients requiring external ventricular drainage consistent with AHA/ASA guidelines or local institutional guidelines are eligible.

#### **Exclusion Criteria**

1. Time of symptom onset cannot be reliably assessed.
2. Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms.
3. Intracerebral hematoma considered to be related to trauma.
4. ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria).
5. Subject considered a candidate for immediate surgical intervention by the neurosurgery service.
6. Pregnancy, parturition within previous 30 days, or active lactation.
7. Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH.
8. Platelet count of less than 50,000/mm<sup>3</sup>.
9. Known sensitivity to nicardipine or clevidipine.
10. Patient's living will precludes aggressive ICU management.
11. Patients with allergies to soybeans, soy products, eggs, or egg products.
12. Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.
13. Patients with severe aortic stenosis.

## **SCREENING AND ENROLLMENT**

### **Screening of potential subjects**

All subjects 18 years or older but less than 90 years old who present to the study sites with clinical symptoms consistent with an ICH demonstrated on brain imaging are to be screened for study eligibility. Data collected and tests performed include demographics and vital signs, medication and medical history, and laboratory measurements required as part of standard care for Emergency Department (ED) admissions or interhospital transfers. The site can designate any number of qualified personnel (ED physicians, stroke team members, ICU physicians) who are familiar with study protocol and process to register enrollment and initiate therapy for blood pressure control. An electronic advisor within the electronic order-entry system informed providers about the trial, asked about relative contraindications to the IV clevidipine or alternate IV antihypertensive agent, and, if none were present, guide providers to order the either IV clevidipine or alternate IV antihypertensive agent (depending upon the hospital). Enrollment occurs at the time of initiation of either IV clevidipine or alternate IV antihypertensive agent and can occur in the ED or ICU during a given hospitalization.

### **Eligibility based on SBP**

At least two readings of SBP of 150 mm Hg or more, but lower than 220 mm Hg) between symptom onset and the initiation of IV antihypertensive treatment will be required for eligibility. Treatment could be initiated before enrollment to lower the SBP to less than 150 mm Hg, which is consistent with guidelines from the consistent with the AHA/ASA guidelines<sup>1</sup> and the ESO-Karolinska Stroke Update Conference<sup>32</sup> but patients are not eligible if the SBP was already reduced to less than 150 mm Hg before enrollment and therefore not requiring any further IV antihypertensive medication intervention. Patients who were already started on IV clevidipine at designated non-clevidipine hospitals or on nicardipine or nitroprusside at designated clevidipine hospitals prior to enrollment will not be eligible.

### **Time of enrollment**

The time of enrollment will be the time that IV infusion of titratable antihypertensive medication is initiated such as clevidipine or nicardipine. Patients may have received shorting acting medication as IV boluses including labetalol, hydralazine, or enalaprilat prior to initiation of IV infusion of titratable antihypertensive medication and will be interfere with the determination of time of enrollment.

### **Inclusion of subjects and informed consent**

All participating patients (or legal surrogates) will be given an information sheet that says ‘the hospital is participating in research that is assessing best method to achieve the BP goals specified in the national guidelines for management of ICH to standardize stroke care around the world’ and will explain the need for data collection (in-hospital) and follow-up assessment. The document will clarify that the patient’s treatment of elevated BP is consistent with what patients would receive as best practices within the institution and is not changed for participation in the study. The standard withdrawal of consent or the opt-out consent process will be used should a subject decline to participate at any time during the study, either for the collection of medical information or the 90- or 180-day follow-up. The opt-out consent is a more robust method to ensure that data on the primary endpoint is as complete as possible. The consent process used for sites will be consistent with the local approval received. We will use this method of inclusion to prevent delays in treatment, to increase enrollment, to allow for patients unable to consent to participate, and to increase data validity and quality.<sup>36</sup> The use of this design is supported by the following: (i) the treatment of elevated BP is consistent with standard of care and national guidelines; (ii) the medications used are to be used according to approved indications and recommended doses; (iii) the treatment of elevated BP is not affected by participation in the study; and (iv) the subject is not facing any additional risk by inclusion in the study. Thus, a participant is any subject for whom consent for data collection and follow-up has been obtained. The design avoids the responder bias in patients (or surrogates) as a result of thinking that they may have received ‘non-standard’ care because of participation in “an experiment.”

## **MANAGEMENT DURING SBP TREATMENT**

### **BP measurement and monitoring**

Once IV antihypertensive medication is initiated, heart and respiratory rates and transcutaneous oxygen saturation are to be monitored continuously. BP may be monitored regularly according to the below schedule with an automated BP monitor according to institutional protocol. All measurements are to be recorded with subjects in a recumbent position and with elevation of the head of the bed not exceeding 15°. Intra-arterial BP recording is not mandated but can be used by the treating physician based on medical indications. BP measurements are recommended to be taken on the following schedule:

During the first hour after IV clevidipine or alternate IV antihypertensive regimen started:

Every 5 minutes for the first 15 minutes after IV clevidipine or alternate IV antihypertensive regimen is started

Every 15 minutes for the remainder of the first hour, unless the dose is being adjusted (see next bullet point)

Every 5 minutes for 15 minutes during dose adjustments

At least every 30 minutes while receiving IV clevidipine or alternate IV antihypertensive regimen


More frequent measurements are recommended if prominent BP changes are observed as determined by the treating physician.

### **Management of anticoagulant-related ICH**

The management of anticoagulant-related ICH should occur concurrent to SBP reduction in appropriate patients. The AHA/ASA guidelines<sup>1</sup> state that treatment should be administered when clinically significant anticoagulant levels are suspected on the basis of type and timing of anticoagulant dosing rather than waiting for results of blood tests (see Figure 3). The guidelines state “four-factor prothrombin complex concentrate (PCC) is superior to plasma for warfarin-associated ICH to rapidly replace vitamin K–dependent coagulation factors and should be given with IV vitamin K to re-establish vitamin

K-dependent coagulation factor production. Reversal of the anticoagulant effect of direct thrombin inhibitors and factor Xa inhibitors can be performed rapidly with specific reversal agents (idarucizumab and andexanet alfa, respectively) when available. When specific reversal agents are not available, aPCC or 4-F PCC may promote hemostasis in patients on direct thrombin inhibitors and factor Xa inhibitors. Renal Replacement Therapy (RRT) may reduce dabigatran concentration.”

Figure 3. Management of anticoagulant related ICH. Adapted from AHA/ASA guidelines<sup>1</sup>



## Surgical evacuation

The AHA/ASA guidelines<sup>1</sup> acknowledge that current evidence does not support specific recommendations for selecting candidates for surgery. As a primary recommendation, minimally invasive hematoma evacuation with endoscopic or stereotactic aspiration, with or without thrombolytic use, is safe and may be useful to reduce mortality. The guidelines suggest that in patients with ICH volume >20 ml or >30 ml with GCS score 5-12, minimally invasive surgery (endoscopic or stereotactic aspiration with or without thrombolytics can be useful to reduce mortality (Class of recommendation 2A, benefit exceeds risk, level of evidence B-R, moderate quality evidence from one of more randomized clinical trial or meta-analysis of randomized controlled trials) but remains uncertain in regards to improving functional outcome (2B, benefit exceeds risk, weak, might be reasonable or considered, level of evidence B-R, moderate quality evidence from one of more randomized clinical trial or meta-analysis of randomized controlled trials) compared with best medical treatment.

## Principles of sedation

Sedation is sometimes required to avoid pain and discomfort, even though it can obscure neurological examination and cause hypotension. The protocol does not provide any specific guidance but recommends an assessment-driven protocol that mandates regular pain and sedation assessment using

validated tools, provides clear guidance on medication choice and dosing, and makes treating pain a priority over providing sedatives consistent with the clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the ICU (conditional recommendation, moderate quality of evidence).<sup>37</sup> The guidelines suggest using acetaminophen and low-dose ketamine (1–2 µg/kg/hour) as an adjunct to opioid therapy to reduce opioid consumption in adults admitted to the ICU (conditional recommendation, very low quality of evidence). The guidelines also suggest using either propofol or dexmedetomidine over benzodiazepines for sedation in critically ill, mechanically ventilated adults (conditional recommendation, low quality of evidence) because of improved short-term outcomes, such as ICU length of stay, duration of mechanical ventilation, and delirium.

### **Renal evaluation**

IV 0.9% sodium chloride (20 mEq/KCl added) is to be administered at 1 ml/kg/hour unless contraindicated as determined by the treating physician. Urine output volumes are quantitated as part of standard ICU care. The quantitation of input and output on a daily basis is routine practice to ensure euvolemia in ICH patients.

### **Cardiac monitoring**

A 12-lead electrocardiogram (EKG) is recommended at baseline. Continuous 7-lead, 3- channel ST-segment monitoring is to be performed for 24 hours during the infusion of IV clevidipine/alternate IV antihypertensive regimen. Significant ST-segment shift suggestive of myocardial ischemia is defined as horizontal or down sloping ST depression 0.1 mV below baseline or upward ST elevation 0.1 mV above baseline, lasting 1 minute, and separated from other episodes of ST-segment. Additional creatinine kinase and troponin-T samples is to be drawn when clinically indicated or when EKG changes suggest myocardial ischemia.

## **IN HOSPITAL ASSESSMENTS**

### **Clinical assessments**

Frequent neurological and vital sign assessments of patients with ICH are indicated to identify neurological deterioration and prevent secondary complications according to AHA/ASA guidelines<sup>1</sup>. The guidelines further state that in patients with ICH of higher clinical severity, neurological assessments are typically performed hourly for the first 24 hours or until the ICH is stable. Each subject is to be admitted in the ICU or stroke unit for a 24- hour observation period. Subjects are to be examined every 60 minutes by nursing staff, with a comprehensive neurologic examination performed at 2-hour intervals. Neurological deterioration is defined as a decrease of 2 points or more decrease in GCS or an increase of 4 points or more on NIHSS scores from baseline or the last performed GCS or NIHSS score that persists for 8 hours or longer. Each episode of neurological deterioration is to be evaluated and managed under the direct supervision of a stroke neurologist or neurointensivist. After neurological deterioration is detected, IV fentanyl or midazolam infusion should be discontinued (if being used) to ensure that an adequate neurological examination can be performed. A non-contrast CT scan is to be performed; based on the results, and appropriate neurological or neurosurgical intervention should be performed. Neurological status is to be assessed by the NIHSS score by the study investigator at 24 (±3) hours post enrollment. As standard of care, brief history and physical examinations should be performed daily while the subject is in the hospital.

## **Radiological assessments**

The study does not require any neuroimaging to be performed that is not required by clinical criteria or institutional protocol. However, the study recognizes that serial CT scans are recommended by AHA/ASA guidelines<sup>1</sup> in patients with ICH and/or IVH within the first 24 hours after symptom onset and may be useful to evaluate for hematoma expansion. (Class of recommendation 2A, benefit exceeds risk, level of evidence B-NR, moderate quality evidence from one of more non-randomized studies, observational studies, registry data). In patients with ICH and/or IVH and low GCS or neurological deterioration, serial CT scans within the first 24 hours after symptom onset may be useful to evaluate for hematoma expansion, development of hydrocephalus, brain swelling, or herniation. (Class of recommendation 2A, benefit exceeds risk, level of evidence B-NR, moderate quality evidence from one of more non-randomized studies, observational studies, registry data). Therefore, the baseline and non-contrast head CT scan at 24 ( $\pm 8$ ) hours post-enrollment if site performs as standard of care will be submitted to central neuroimaging core laboratory for identification of hematoma expansion. Hematoma enlargement is defined by a 33% greater increase in hematoma volume at 24 hours compared with baseline hematoma volume.<sup>38</sup> Brain MRI acquired between 24 hours and 7 days if performed as standard of care will be submitted to central neuroimaging core laboratory for identification of new ischemic lesions defined by the presence of hyperintensities on DWI if hyperintense signal is relative to surrounding tissue and distinct from ICH with correlation on apparent diffusion coefficient map.

## **Laboratory assessments**

It is expected that routine clinical laboratory surveillance, including platelet count hemoglobin, hematocrit, and complete chemistry panels, must be performed at baseline, 24 hours, 48 hours, and 72 hours and will be available for ascertainment of AKI.

## **POST ACUTE HOSPITALIZATION CARE**


### **Post-discharge care**

The protocol does not provide any specific guidance. Long-term care and rehabilitation after discharge may be based according to principles outlined in previous guidelines particularly the AHA clinical practice guidelines,<sup>39,40</sup> which provide a comprehensive review of evidence-based principles of post-hospitalization care.

### **Post-discharge follow-up**

Post-discharge follow-up for CLUTCH is planned at 90 ( $\pm 14$ ) days and 180 ( $\pm 14$ ) days, either through telephone contact and/or in-person clinical evaluation by a qualified investigator (certified in assessment of mRS scores) who did not participate in the recruitment or treatment of the subject during the acute hospitalization and should be designated for the duration of the trial. Each subject will be assigned a score on the mRS (which assesses the degree of disability or dependence in daily activities, with scores ranging from 0 [no symptoms] to 6 [death] using a validated structured interview<sup>41,42</sup> We will recommend the algorithm proposed by Bruno et al.<sup>43</sup> to assign the mRS grade (see Figure 4). The expected time to assign a grade based on the algorithm is approximately 2 minutes. In cases of persistent disagreement between patients and their caregivers, the caregivers' answers will be accepted as more accurate.<sup>44</sup>

Figure 4. Algorithm proposed by Bruno et al.<sup>43</sup> to assign the mRS grade



During the telephone interview, the site staff will also obtain information regarding death and the cause of death and recurrent stroke, as pertinent and available. All subjects are followed to 180 days ( $\pm 30$  days), death, or withdrawal of consent, whichever comes first. Thus, regardless of whether or not a subject has completed the study intervention, all follow-up procedures are to be performed according to the standard schedule. We will use a mobile phone-based questionnaire to assess mRS.<sup>45,46</sup> The application will be designed with friendly interface to be installed on smartphone Mac operation system (OS) or Android OS. The person performing mRS will be able to use the application and will link to the central data repository.

**DATA ASCERTAINMENT AND COLLECTION SCHEDULE**

The schedule of data collection is presented in Table 2. The research team will retrospectively extract a de-identified data set from the electronic medical records including SBP data (at a rate of 1 sample per 5 minutes), and infusion rate for first 24 hours post enrollment.


Table 2. Schedule of data ascertainment and collection							
	Baseline	24 hours	48 hours	72 hours	Day 7 or discharge (whichever comes first)	Day 90 (phone/ in person visit)	Day 180 (phone/ in person visit)
Screening Eligibility	×						
Enrollment	×						
Demographics/ED examination	×						

Medical history	×						
Cardiology/ 12 lead EKG	×						
Prior medications	×						
Vital signs	×	×	×	×			
GCS score	×	×					
NIHSS score	×	×					
Laboratory tests	×	×	×	×	x		
CT scan head	×	*					
Clevidipine/alternate IV medication administration	×	×	×	×			
Additional IV medication	×	×	×	×			
MRI brain				*			
Hospital discharge summary					×		
Concomitant medications		×	×		×		
Concomitant procedures		×	×		×		
SAEs		×				×	×
Modified Rankin scale						×	×
Follow up						×	×
End of Study							×

Figure 5 highlights the principles of data ascertainment and collection with particular emphasis on reducing manual data entry and the complexity of case report forms. \*, to be performed if clinically indicated (not mandated by trial).

Figure 5. The principles of data ascertainment and collection.





## STATISTICAL CONSIDERATIONS

### Sample size calculation

This is a multi-center non-randomized cluster design trial with the primary aim of testing the superiority of IV clevidipine versus alternate IV antihypertensive medication in patients with ICH. The primary endpoint is the proportion of patients who reached three consecutive SBP recordings between 130-150 mm Hg within 60 minutes. Formally, we will test the null hypothesis  $H_o: \mu_p - \mu_s \leq \Delta$  ( $p$  is not superior to  $s$ ) against the alternative  $H_A: \mu_p - \mu_s > \Delta$  ( $p$  is superior to  $s$ ), where  $\Delta$  is the minimal clinically important difference (MCID), which we set at 7.5%. The overall Type I error ( $\alpha$ ) is set at 0.05 and power at 0.8 ( $\beta = .2$ ), providing a sample size of 808 participants.<sup>47</sup> Power and sample size for the design is calculated under the assumption that the observed values in patients treated with alternate IV antihypertensive medication will be 15% (see Table 2). The proportion is estimated based on the results of the ATACH-2 trial.<sup>6</sup> To account for attrition, missing data and failures to treat as randomized, the statistically necessary sample size was inflated by 20%, giving a target enrollment of 970 participants. For certain analysis such as hematoma expansion and new cerebral ischemic lesions, the sample size is based on availability since the trial does not require neuroimaging that is not performed as routine care.

Table 2. Assumptions used for sample size calculations

Alternate IV antihypertensive regimen	IV clevidipine treatment	Alternate IV antihypertensive regimen	IV clevidipine treatment	Total number	Inflated by 20%
15%	22.5%	424	424	848	1018
15%	25%	250	250	500	600
20%	27.5%	505	505	1010	1212

### Interim analysis

The CLUTCH trial is a pragmatic trial evaluating existing standard of care at hospitals and therefore monitoring for harm or monitoring adherence to interventions will not be required<sup>48</sup>. CLUTCH trial will recruit participants post-treatment and unblinded to the treatment allocation requiring monitoring for evidence of possible selection bias. The interim analysis will identify any imbalances between the two groups<sup>49</sup> using either global test of balance across all prognostic factors, separate and independent tests, or as estimates of differences along with confidence intervals. The analysis of baseline characteristics will be performed<sup>50</sup> if any clearly identified imbalance are identified, changes to strategies of identification and recruitment may be required. Alternatively, the analysis plan may require pre-specified unadjusted (other than adjustment for cluster-level co-variables) primary analysis to an adjusted (for individual-level covariates) primary analysis. The Steering Committee will be presented blinded data at two time points. The report will not identify the clevidipine and non-clevidipine group but refer to as Group A and Group B<sup>51</sup>. Steering Committee will decide whether any differences (between study arms) in total numbers recruited or the individual-level characteristics across intervention conditions are clinically important, and whether there is evidence that the differences are unlikely to be due to chance alone<sup>51</sup>. The Steering Committee will decide whether if the full trial were to exhibit such imbalances, would this imbalance question the reliability and validity of the results. In the event that selection bias is identified, the committee will consider: (1) investigation of whether all ICH patients are being assessed as eligible between the two groups, and (2) changing pre-specified primary analysis from unadjusted to covariate adjusted and add a fully pre-specified covariate adjustment will be included as a sensitivity analysis (using a propensity score approach). There are two proposed interim assessment points. The first will occur after approximately 50% of patients have been recruited and the second will take place after 75% of patients have been recruited.

The plan presented above is used instead of a sequential design used in individual patients randomized trials for the reasons mentioned above (including differences in recruitment rates in clevidipine and non-clevidipine hospitals) and would have involved two interim analyses conducted after one-third and two-thirds of subject accrual, and a final analysis if the study runs to full term. Test statistics/p-values at each analysis would have been compared to the following boundaries, allowing for early stopping with a conclusion of non-superiority, or early termination for futility. An O'Brien-Fleming type<sup>52</sup> spending rule will be used to control the overall Type I error. The futility of continuing the study will be based on conditional power.<sup>53</sup> The statistical analysis plan indicates the test statistic and corresponding two-sided p-value thresholds for each interim analysis, such that stopping the trial early for futility and overwhelming efficacy maybe considered (see Table 3).

Table 3. Principles for determining futility and overwhelming efficacy during interim analysis			
Alternate IV antihypertensive regimen	IV clevidipine treatment	p-value for overwhelming efficacy	p-value for futility
160	160	<0.0161	≥0.652
640	320	<0.0203	≥0.293
485	485	Complete	Complete

### Minimal clinically important difference

In previous randomized controlled trials comparing IV nicardipine vs nitroprusside and IV nicardipine vs labetalol have used a MCID of ≥7.5% to demonstrate superiority in the proportion of patients reaching BP treatment goals within 30 or 60 minutes.<sup>54,55</sup> An increase in proportion of patients who reach therapeutic goal (<150 mm Hg) within 60 minutes is expected to increase the proportion of patients who

achieve functional independence at 90 days by 50% (relative increase) based on secondary analysis of ATACH 2. An increase in proportion of patients who achieve therapeutic goal (<150 mm Hg) within 60 minutes by 7.5%, assuming that 46% of the patients achieve functional independence at 90 days (combined value from ATACH 2 and INTERACT 2 that may be expected in “non-clevidipine group”),<sup>27</sup> will lead to an increase in functional independence at 90 days by absolute value of 1.75 in every 100-patient cohort. For simple and safe therapies for acute stroke, MCIDs derived from observations of actual physician behavior and medical guidelines have ranged between 1%–1.5%<sup>56-59</sup> In a survey of 122 academic stroke neurologists, the median MCID was 1.3% in the absolute increase needed in the proportion of patients achieving functional independence at 3 months to consider a novel, safe agent as clinically worthwhile.<sup>57</sup>

### **Statistical analysis**

The pre-specified primary analysis for primary endpoint will be conducted under the intention-to-treat principle, with adjustment for the effects of age, GCS score, and presence or absence of IVH. The analysis of the dichotomized 3-month mRS score (3 to 6 vs. 0 to 2) will be based on the generalized linear model with log-link function with Poisson distribution (rather than binomial distribution, because of convergence issues). Missing data for mRS may be imputed with the use of the multiple-imputation method that generates and analyzes 100 samples (with the use of a computer simulation) of the trial data, each with a variable imputed value for the missing data, and results are subsequently compiled.

### **Missing data**

Missing data is inevitable in a large-scale trial, but we do not expect this to be a major issue due to the short-term follow-up and mortality, and data collection that is both largely automated and consistent with routine care. We have inflated the sample size to account for the expected patient loss. When data are missing completely at random (MCAR), complete-case analysis does not bias the treatment estimates but may reduce power. When the probability that data are missing is a function of observed data elements, the mechanism is missing at random (MAR). Under the MAR mechanism unbiased estimates are obtained using covariate adjustment, which is already reflected in our data analysis plan. Further, if the missing data exceeds expectation (> 10-15% of enrolled cases), we will estimate group effects and test hypotheses using multiple imputation (MI) under a various pattern-mixture schemes. All MI complete datasets will be analyzed with standard statistical methods and Rubin’s combination rule to obtain a point estimate. Both estimates from MI and complete case analyses will be reported. Multiple imputation under MAR mechanisms is available in SAS/STAT® multiple imputation procedure (SAS/STAT software, Version 15.2 of the SAS System for Windows. Copyright © 2020 SAS Institute Inc., SAS Institute Inc., Cary, North Carolina, USA). Missing data become problematic for data missing not at random (NMAR). Sensitivity analyses that replace missing data with observations over the range of plausible values will be used to account for potential NMAR.

### **Heterogeneity of treatment effects**

We will use the Patient-Centered Outcomes Research Institute (PCORI) standards for testing heterogeneity of treatment effects (HTE).<sup>60</sup> We will assess consistency of treatment effect in 10 pre-specified univariate subgroups: age (<55, 56-79, ≥80 yrs), time interval from symptom onset to initiation of treatment (<6 hours and ≥6 hours), initial SBP (<180 mm Hg and ≥180 mm Hg), initial GCS score (<8 and ≥8), initial hematoma volume (<30 cc and ≥30 cc), location of hematoma (basal ganglia or thalamus versus lobar versus infratentorial), interfacility transfer (yes, no), intraventricular extension (yes, no), site recruitment (<median value and ≥median value), and baseline serum glucose (<140 mg/dl, ≥140 mg/dl). The expected number of subjects in CLUTCH in each of these subgroups ranges from 150 to 500 subjects. The subgroups have been pre-specified based on prognostic significance.<sup>61,62</sup> The relative

risk (with 95% CI) will be calculated and displayed graphically as forest plots. We will estimate the treatment effects (net benefit) *within each subgroup* in separate analyses ( $E_1$  and  $E_2$ , respectively). A test for statistical interaction comparing the two subgroups will be calculated based on the subgroup treatment effects ( $E_1$  and  $E_2$ ) and their corresponding standard errors. The  $z$  value which gives a test of the null hypothesis that in the population the difference between subgroups ( $d$ ) is zero by comparing the value of  $z$  to the standard normal distribution will be used to provide the p-value. The Gail-Simon test will be used for qualitative interaction if IV clevidipine in one subgroup shows harmful effects and another shows benefit.<sup>63</sup> An alternative and perhaps more typical approach is to include treatment arm by subgroup interaction effects in a linear model. However, interaction models do not add to the analysis because these interaction effects will be seriously underpowered.<sup>64,65</sup>

### **Secondary analyses**

There are 11 secondary analyses comparing median time to reach target SBP, the proportion of subjects with ICH who reach SBP target within 30 minutes of enrollment, the time-in-target range in first 24 hours, rates of hematoma expansion; new ischemic lesions on MRI, AKI, and functional independence at/within 90-days, and comparing the SD of the SBP in first 8 hours after enrollment. Mean values will be compared using independent sample two tailed t-test. If the distribution of the data is not normal, Wilcoxon Signed-Rank test for data with unequal variances may be considered. For median values, comparisons will be made using Kruskal-Wallis test. This overall approach is similar to the above proposed primary outcome analysis. Nominal and ordinal scale outcomes will be analyzed using nominal and ordinal logistic regression with standard error computed by the method of generalized estimating equations.<sup>66</sup> Depending on the observed distribution of the SD outcome, a linear mixed model or count data model such as Poisson regression will be used. Depending on the scale of the specific variable, treatment effect estimates will be presented as unadjusted and adjusted ORs, difference of proportions and means (with 95% CIs). Confidence intervals excluding 1.0 for ORs, and zero for risk and mean differences, provide additional support for the superiority of IV clevidipine. Beyond age, GCS score, hematoma volume, and presence or absence of IVH, additional covariates will be identified from previous studies as those factors having a meaningful impact on these outcomes.<sup>61,62</sup> In addition, variable selection methods such stepwise regression or the least absolute shrinkage and selection operator (LASSO model)<sup>151</sup> may be applied to assess the best set of covariates to include in a particular regression model. These analysis results will be treated as supportive evidence (or lack thereof) of the treatment effect of IV clevidipine, rather than conclusive evidence. Efficacy analyses of the ordinal shift in mRS score will be done for the full range of adjudicated mRS scores (0–6) using the Cochran-Mantel-Haenszel shift test, followed by proportional odds logistic regression subject to the validity of shift analysis model assumptions. We may use multivariate analysis to compare the differences in new ischemic lesions on MRI between clevidipine and non-clevidipine groups to adjust for differences in time periods of MRI acquisition if there are differences identified between the two groups.

### **Tertiary analyses**

We will also confirm the prognostic significance of the primary endpoint, SBP target with stability (defined as achieving a SBP of less than 150 mm Hg and greater than 130 mm Hg with two subsequent consecutive recordings at least 15 minutes apart with SBP of less than 150 mm Hg and greater than 130 mm Hg). We will evaluate the relationship between achieving SBP target with stability within 60 minutes with HE within 24 hours, new cerebral ischemic lesions on MRI within 7 days, AKI, and functional independence at 180 days. A logistic regression model will be used to adjust for age, initial GCS score, hematoma volume and presence or absence of IVH. We will also evaluate the outcome variable of mRS entered as an ordinal variable in the model. We will also evaluate the relationship between time to reach SBP with stability entered as a continuous variable with the outcomes of HE within 24 hours, new cerebral ischemic lesions on MRI within 7 days, AKI, and functional independence at 180 days. A linear

regression model will be used that will adjust for age, initial GCS score, hematoma volume and presence or absence of IVH. We will also evaluate the outcome variable of mRS entered as an ordinal variable in the model.

### **Analysis of the data from stepped wedge cluster**

The nested stepped wedge design is included as a sensitivity design. The study is not powered based on the stepped wedge design. We will use the modeling approach proposed by Hussey and Hughes<sup>67,68</sup> to analyze data from a stepped wedge component of the trial. It involves fitting a linear mixed model:

$$Y_{ijl} = \beta_0 + \beta_j + u_i + e_{ijl}$$

where  $i$  indexes the cluster,  $j$  indexes time and  $l$  indexes the individual, with  $Y_{ijl}$  a continuous outcome. The term  $u_i \sim N(0, \sigma_u^2)$  represents a cluster-level random effect,  $e_{ijl} \sim N(0, \sigma_e^2)$  the individual error terms,  $X$  is a binary variable representing exposure to the treatment (1 for treatment, 0 otherwise),  $\theta$  is the treatment effect. Following Hussey and Hughes' recommendations,  $\beta_j$  represents a fixed categorical effect to model the underlying secular trend ( $\beta_T = 0$  for identifiability where  $T$  is the total number of measurement periods) and  $\beta_0$  an intercept term which represents the population average during the first time interval. The  $u_i$  represents the time invariant deviation of the cluster from the population average. The intraclass correlation coefficient (ICC) which, under this model, is assumed constant over time.

### **Safety analyses**

Safety analyses will include between-group comparisons of SAEs by patient, Standardized Medical Dictionary for Regulatory Activities (MedDRA) code, and organ system.

### **Imbalance in recruitment between clusters**


One of the challenges in cluster trials is a possible imbalance in cluster size, which if severe can have influence on the power, particularly if the number of clusters is low and/or the intraclass correlation coefficient is high.<sup>69</sup> Cluster size recruitment varies depending upon multiple factors such as (i) overall number of ICH patients who maybe candidates in the cluster and (ii) the recruitment uptake, meaning proportion included from eligible fraction of subjects, which may vary among clusters.<sup>69</sup> Cluster trials have used the 80/20 rule<sup>70</sup> based on the Pareto principle to define imbalance that may affect the power of the study; this states that compromise of power is a concern if 80% of the recruitment is derived from 20% of the sites. In an analysis of the largest trials in critical care, the SAFE, NICE-SUGAR, RENAL, CHEST and ADRENAL trials,<sup>70</sup> 80% of the patients were recruited by the highest recruiting ranging from 41% to 70% of ICUs rather than 20%, suggesting that an imbalance of large magnitude is infrequent. We may use serial examination of the Lorenz curve and Gini coefficient, for example at 25% and 50% of enrolment, as a quality marker for assessing external validity and for comparing recruitment between clusters in order to make certain that potential imbalance is not impactful.

### **Analysis of the data from observational cohort**

The number of patients in the observational cohort of patients with ICH with initial SBP  $\geq 220$  mm Hg is expected to be approximately 200 patients. We will evaluate the relationship between measures of SBP control that include the mean of SBP measures between 1 and 24 hours; variability of SBP (the SD of the same measures between 1 and 24 hours); and magnitude of early reduction of SBP (the difference between randomization SBP and the lowest attained SBP within the first hour), with HE within 24 hours, new cerebral ischemic lesions on MRI within 7 days, AKI, and functional independence at 180 days. A logistic regression model will be used to adjust for age, initial GCS score, hematoma volume, and presence or absence of IVH. We also plan to use modeling of time-based longitudinal data as group-based

trajectory modeling to identify SBP trajectories from the timing of hospital arrival through the first 24 hours after treatment. The longitudinal SBP data will be fitted to a maximum likelihood method as a mixture of multiple latent trajectories (linear or take more complex shapes according to the polynomial functions) in a censored normal model with a polynomial function of time as described previously.<sup>71</sup> Logistic regression models will be used to elucidate the association of primary and secondary outcomes with trajectory grouping.

Signature:



Adnan I. Qureshi, MD, Professor of Neurology and Program Director  
Endovascular Surgical Neuroradiology program, University of Missouri, Columbia, MO.

CEO and Founder, Zeenat Qureshi Stroke Institute

Date:

July 31, 2024

## REFERENCES

1. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. *Stroke* 2022;53(7):e282-e361. DOI: 10.1161/STR.0000000000000407.
2. Graffagnino C, Bergese S, Love J, et al. Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial. *Cerebrovasc Dis* 2013;36(3):173-80. (In eng). DOI: 10.1159/000351149.
3. Buckley LF, Baker WL, Van Tassel BW, et al. Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. *Hypertension* 2023;80(2):305-313. DOI: 10.1161/HYPERTENSIONAHA.122.20141.
4. Palaiodimou L, Joundi RA, Katsanos AH, et al. Association between blood pressure variability and outcomes after endovascular thrombectomy for acute ischemic stroke: An individual patient data meta-analysis. *Eur Stroke J* 2023;23969873231211157. (In eng). DOI: 10.1177/23969873231211157.
5. Manning LS, Rothwell PM, Potter JF, Robinson TG. Prognostic Significance of Short-Term Blood Pressure Variability in Acute Stroke. *Stroke* 2015;46(9):2482-2490. DOI: 10.1161/STROKEAHA.115.010075.

6. Qureshi AI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. *N Engl J Med* 2016;375(11):1033-43. (In eng). DOI: 10.1056/NEJMoa1603460.
7. Kellum JA, Lameire N., Aspelin, P., Barsoum, R. S., Burdmann, E. A., Goldstein, S. L., Herzog, C. A., Joannidis, M., Kribben, A., Levey, A. S., MacLeod, A. M., Mehta, R. L., Murray, P. T., Naicker, S., Opal, S. M., Schaefer, F., Schetz, M., & Uchino, S. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Nature Publishing Group.
8. Adverse Event Detection, Processing, and Reporting.
9. Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. *Circulation* 2008;118(2):176-87. (In eng). DOI: 10.1161/circulationaha.107.723874.
10. Hawkes MA, Rabinstein AA. Acute Hypertensive Response in Patients With Acute Intracerebral Hemorrhage: A Narrative Review. *Neurology* 2021;97(7):316-329. (In eng). DOI: 10.1212/wnl.0000000000012276.
11. Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology* 2006;66(8):1175-81. (In eng). DOI: 10.1212/01.wnl.0000208408.98482.99.
12. Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. *Stroke* 1997;28(12):2370-5. (In eng). DOI: 10.1161/01.str.28.12.2370.
13. Rodriguez-Luna D, Piñeiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. *Eur J Neurol* 2013;20(9):1277-83. (In eng). DOI: 10.1111/ene.12180.
14. Dandapani BK, Suzuki S, Kelley RE, Reyes-Iglesias Y, Duncan RC. Relation between blood pressure and outcome in intracerebral hemorrhage. *Stroke* 1995;26(1):21-4. (In eng). DOI: 10.1161/01.str.26.1.21.
15. Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. *Stroke* 2013;44(7):1846-51. (In eng). DOI: 10.1161/strokeaha.113.001212.
16. Vemmos KN, Tsvigoulis G, Spengos K, et al. Association between 24-h blood pressure monitoring variables and brain oedema in patients with hyperacute stroke. *J Hypertens* 2003;21(11):2167-73. (In eng). DOI: 10.1097/00004872-200311000-00027.
17. Kim-Han JS, Kopp SJ, Dugan LL, Diringer MN. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. *Stroke* 2006;37(10):2457-62. (In eng). DOI: 10.1161/01.STR.0000240674.99945.4e.
18. Powers WJ, Zazulia AR, Videen TO, et al. Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. *Neurology* 2001;57(1):18-24. (In eng). DOI: 10.1212/wnl.57.1.18.
19. Kate M, Gioia L, Jeerakathil T, et al. Aggressive blood pressure reduction is not associated with decreased perfusion in leukoaraiosis regions in acute intracerebral hemorrhage patients. *PLoS One* 2019;14(3):e0213645. (In eng). DOI: 10.1371/journal.pone.0213645.
20. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med* 2013;368(25):2355-65. (In eng). DOI: 10.1056/NEJMoa1214609.
21. Toyoda K, Koga M, Yamamoto H, et al. Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. *Ann Neurol* 2019;85(1):105-113. (In eng). DOI: 10.1002/ana.25379.
22. Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials. *J Neurol Neurosurg Psychiatry* 2017;88(4):339-345. (In eng). DOI: 10.1136/jnnp-2016-315346.
23. Chang JJ, Armonda R, Goyal N, Arthur AS. Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage. *Neural Regen Res* 2019;14(7):1116-1121. (In eng). DOI: 10.4103/1673-5374.251189.
24. Tanaka E, Koga M, Kobayashi J, et al. Blood Pressure Variability on Antihypertensive Therapy in Acute Intracerebral Hemorrhage. *Stroke* 2014;45(8):2275-2279. DOI: 10.1161/STROKEAHA.114.005420.

25. de Havenon A, Majersik JJ, Stoddard G, et al. Increased Blood Pressure Variability Contributes to Worse Outcome After Intracerebral Hemorrhage. *Stroke* 2018;49(8):1981-1984. (In eng). DOI: 10.1161/strokeaha.118.022133.
26. Manning L, Hirakawa Y, Arima H, et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. *Lancet Neurol* 2014;13(4):364-73. (In eng). DOI: 10.1016/s1474-4422(14)70018-3.
27. Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. *Lancet Neurol* 2019;18(9):857-864. (In eng). DOI: 10.1016/s1474-4422(19)30196-6.
28. Hemming K, Taljaard M, Forbes A. Analysis of cluster randomised stepped wedge trials with repeated cross-sectional samples. *Trials* 2017;18(1):101. (In eng). DOI: 10.1186/s13063-017-1833-7.
29. Qureshi AI, Huang W, Lobanova I, et al. Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Neurol* 2020;77(11):1355-1365. (In eng). DOI: 10.1001/jamaneurol.2020.3075.
30. Li Q, Warren AD, Qureshi AI, et al. Ultra-Early Blood Pressure Reduction Attenuates Hematoma Growth and Improves Outcome in Intracerebral Hemorrhage. *Ann Neurol* 2020;88(2):388-395. (In eng). DOI: 10.1002/ana.25793.
31. Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH Score. *Stroke* 2001;32(4):891-897. DOI: 10.1161/01.STR.32.4.891.
32. Ahmed N, Audebert H, Turc G, et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018. *Eur Stroke J* 2019;4(4):307-317. (In eng). DOI: 10.1177/2396987319863606.
33. Sandset EC, Anderson CS, Bath PM, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. *Eur Stroke J* 2021;6(2):Xlviii-lxxxix. (In eng). DOI: 10.1177/239698732111012133.
34. Polster SP, Carrión-Penagos J, Lyne SB, et al. Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials. *Oper Neurosurg (Hagerstown)* 2020;20(1):98-108. (In eng). DOI: 10.1093/ons/opaa306.
35. Hanley DF, Thompson RE, Rosenblum M, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. *Lancet* 2019;393(10175):1021-1032. (In eng). DOI: 10.1016/s0140-6736(19)30195-3.
36. Faris H, Dewar B, Fedyk M, et al. Protocol for Deferral of Consent in Acute Stroke Trials. *Neurology* 2023;100(6):292-300. (In eng). DOI: 10.1212/wnl.0000000000201533.
37. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. *Crit Care Med* 2018;46(9):e825-e873. (In eng). DOI: 10.1097/ccm.0000000000003299.
38. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. *Neurology* 2011;76(14):1238-44. (In eng). DOI: 10.1212/WNL.0b013e3182143317.
39. Winstein CJ, Stein J, Arena R, et al. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke* 2016;47(6):e98-e169. (In eng). DOI: 10.1161/str.0000000000000098.
40. Beghi E, Binder H, Birle C, et al. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. *Eur J Neurol* 2021;28(9):2831-2845. (In eng). DOI: 10.1111/ene.14936.
41. Wilson JT, Hareendran A, Grant M, et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. *Stroke* 2002;33(9):2243-6. (In eng). DOI: 10.1161/01.str.0000027437.22450.bd.



42. Wilson JTL, Hareendran A, Grant M, et al. Improving the Assessment of Outcomes in Stroke. *Stroke* 2002;33(9):2243-2246. DOI: 10.1161/01.STR.0000027437.22450.BD.
43. Bruno A, Shah N, Lin C, et al. Improving Modified Rankin Scale Assessment With a Simplified Questionnaire. *Stroke* 2010;41(5):1048-1050. DOI: 10.1161/STROKEAHA.109.571562.
44. Knapp P, Hewison J. Disagreement in patient and carer assessment of functional abilities after stroke. *Stroke* 1999;30(5):934-8. (In eng). DOI: 10.1161/01.str.30.5.934.
45. Cooray C, Matusevicius M, Wahlgren N, Ahmed N. Mobile Phone-Based Questionnaire for Assessing 3 Months Modified Rankin Score After Acute Stroke: A Pilot Study. *Circ Cardiovasc Qual Outcomes* 2015;8(6 Suppl 3):S125-30. (In eng). DOI: 10.1161/circoutcomes.115.002055.
46. Chang H, Zhao J, Qiao Y, et al. Mobile phone application for self-assessment of acute stroke patients: A tool for extended care and follow-up. *Medicine (Baltimore)* 2018;97(26):e11263. (In eng). DOI: 10.1097/md.00000000000011263.
47. Rosner B. Fundamentals of biostatistics.
48. Ellenberg SS, Culbertson R, Gillen DL, Goodman S, Schrandt S, Zirkle M. Data monitoring committees for pragmatic clinical trials. *Clin Trials* 2015;12(5):530-6. (In eng). DOI: 10.1177/1740774515597697.
49. Hemming K, Martin J, Gallos I, Coomarasamy A, Middleton L. Interim data monitoring in cluster randomised trials: Practical issues and a case study. *Clin Trials* 2021;18(5):552-561. (In eng). DOI: 10.1177/17407745211024751.
50. Bolzern JE, Mitchell A, Torgerson DJ. Baseline testing in cluster randomised controlled trials: should this be done? *BMC Medical Research Methodology* 2019;19(1):106. DOI: 10.1186/s12874-019-0750-8.
51. Friede T, Miller F. Blinded Continuous Monitoring of Nuisance Parameters in Clinical Trials. *Journal of the Royal Statistical Society Series C (Applied Statistics)* 2012;61:601-618. DOI: 10.2307/23251162.
52. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics* 1979;35(3):549-56. (In eng).
53. Jennison C, Turnbull B. Group Sequential Methods. Chapman & Hall/CRC Interdisciplinary Statistics Series: Chapman & Hall; 1999.
54. Neutel JM, Smith DH, Wallin D, et al. A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. *Am J Hypertens* 1994;7(7 Pt 1):623-8. (In eng). DOI: 10.1093/ajh/7.7.623.
55. Peacock WF, Varon J, Baumann BM, et al. CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. *Critical Care* 2011;15(3):R157. DOI: 10.1186/cc10289.
56. Fisher M, Albers GW, Donnan GA, et al. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. *Stroke* 2005;36(8):1808-13. (In eng). DOI: 10.1161/01.Str.0000173403.60553.27.
57. Cranston JS, Kaplan BD, Saver JL. Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies. *Stroke* 2017;48(11):2946-2951. DOI: 10.1161/STROKEAHA.117.017496.
58. Samsa GP, Matchar DB. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. *Stroke* 2001;32(3):669-74. (In eng). DOI: 10.1161/01.str.32.3.669.
59. Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. *Cochrane Database Syst Rev* 2014;2014(3):Cd000029. (In eng). DOI: 10.1002/14651858.CD000029.pub3.
60. PCORI. Category 5: Standards for Heterogeneity of Treatment Effects. (<https://www.pcori.org/research-results/about-our-research/research-methodology/methodology-standards-academic-curriculum-3>).
61. Hemphill JC, 3rd, Farrant M, Neill TA, Jr. Prospective validation of the ICH Score for 12-month functional outcome. *Neurology* 2009;73(14):1088-94. (In eng). DOI: 10.1212/WNL.0b013e3181b8b332.
62. Qureshi AI, Safdar K, Weil EJ, et al. Predictors of Early Deterioration and Mortality in Black Americans With Spontaneous Intracerebral Hemorrhage. *Stroke* 1995;26(10):1764-1767. DOI: 10.1161/01.STR.26.10.1764.

63. Lesko CR, Henderson NC, Varadhan R. Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. *J Clin Epidemiol* 2018;100:22-31. (In eng). DOI: 10.1016/j.jclinepi.2018.04.005.
64. Gelman A, Hill J, Yajima M. Why We (Usually) Don't Have to Worry About Multiple Comparisons. *Journal of Research on Educational Effectiveness* 2012;5(2):189-211. DOI: 10.1080/19345747.2011.618213.
65. Gelman A, Hill J, Vehtari A. *Regression and Other Stories*: Cambridge University Press, 2020.
66. Hardin JW, Hilbe JM. *Generalized Estimating Equations*. Chapman and Hall/CRC; 2002.
67. Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. *Contemp Clin Trials* 2007;28(2):182-91. (In eng). DOI: 10.1016/j.cct.2006.05.007.
68. Martin J, Taljaard M, Girling A, Hemming K. Systematic review finds major deficiencies in sample size methodology and reporting for stepped-wedge cluster randomised trials. *BMJ Open* 2016;6(2):e010166. (In eng). DOI: 10.1136/bmjopen-2015-010166.
69. Kerry SM, Bland JM. Unequal cluster sizes for trials in English and Welsh general practice: implications for sample size calculations. *Stat Med* 2001;20(3):377-90. (In eng). DOI: 10.1002/1097-0258(20010215)20:3<377::aid-sim799>3.0.co;2-n.
70. Ramanan M, Billot L, Rajbhandari D, et al. Does asymmetry in patient recruitment in large critical care trials follow the Pareto principle? *Trials* 2020;21(1):378. (In eng). DOI: 10.1186/s13063-020-04279-1.
71. Tanaka K, Koga M, Fukuda-Doi M, et al. Temporal Trajectory of Systolic Blood Pressure and Outcomes in Acute Intracerebral Hemorrhage: ATACH-2 Trial Cohort. *Stroke* 2022;53(6):1854-1862. DOI: 10.1161/STROKEAHA.121.037186.